Rapid and durable response demonstrated in the first placebo-controlled study exploring a short-duration psychedelic for depression
Psychiatric Times, January 25, 2023
Small Pharma, a European psychedelic medicine company announced the results of its Phase 2a clinical trial, treating moderate to severe Major Depressive Disorder (MDD) with DMT-assisted therapy. The trial carries special significance, as it is the first-ever clinical trial attempting to treat a mental health disorder with DMT, the shorter-acting chemical cousin to psilocybin.
Scientists are beginning to unravel the effects of psilocybin mushrooms on bipolar disorder
Psypost, January 21, 2023
Scientists are beginning to unravel the effects of psilocybin mushrooms on bipolar disorder. Research of late has shown psilocybin to improve symptoms of depression, which is particularly burdensome to the quality of life for people with bipolar disorder.
Australia the world’s psychedelic research capital as Ingenu studies psilocybin and MDMA
The Australian, January 10, 2023
Australia is emerging as a leading centre for psychedelic medicine trials.
In Pursuit of Altered States of Consciousness
Herald, January 7, 2023
The highs, the lows and the new “normal”, in Pursuit of Altered States of Consciousness. Dive into this intricate article, journeying the spectrum of humanity’s psychedelic experiences and stories.
What Happens in a Clinical Trial for Psychedelics?
ABC Sydney, January 5, 2023
Josh Szeps from ABC Sydney speaks to Michael Taylor about his experience as a volunteer part of a clinical trial at the Turner Institute for Brain and Mental Health at Monash University.
MAPS PBC Announces Positive Results from Confirmatory Phase 3 “MAPP2” Trial of MDMA-Assisted Therapy for Treatment of PTSD
PR Newswire, January 5, 2023
If approved, MAPS PBC’s MDMA-assisted therapy could be the first psychedelic-assisted therapies used to treat a mental health condition.
New York Lawmakers Introduce Psychedelics Legalization Bill
Forbes, January 4, 2023
A trio of New York state lawmakers has introduced a bill to legalize natural psychedelics, including DMT, ibogaine, mescaline, psilocybin and psilocin.
‘Melding with the MRI machine’: The volunteers taking psychedelic drugs for science
Sydney Morning Herald, January 2, 2023
Michael Taylor was lying in an MRI machine when he had the most joyous experience of his life. He is one of 60 volunteers participating in PsiConnect, the first psychedelic trial in Australia involving healthy participants.
686 Deaths Too Many
Herald Sun, December 30, 2022
SUICIDES in Victoria are at a five-year high, with 686 deaths recorded so far this year.
Could psychedelics be used to treat mental health disorders?
ABC News, November 25, 2022
There is hope that psychedelic medicines might hold the key to treating a range of mental health issues — from anxiety to depression and PTSD.
The Expanding Scope of Psychedelics as Medicines
Blossom in cooperation, and co-published, with Lucid News, November 14, 2022
How the expanding scope of psychedelic medicine research is demonstrating the effectiveness of a single compound (psilocybin/MDMA) across multiple disorders, from PTSD to headache disorders.
“Open the Diagnostic and Statistical Manual of Mental Disorders (DSM-V, psychiatrists’ dictionary), pick any disorder, and you’re likely to see psychedelics research being conducted for it.”
New psychedelic trial to test whether hallucinogenic drug can help cure smoking addiction
7 News, November 13, 2022
The US National Institutes of Health has awarded a grant to scientists at Johns Hopkins University, in the first offer of its kind in half a century.
The study, a randomised controlled trial expected to start later this year, will investigate whether psilocybin, the psychedelic compound found in “magic mushrooms”, can help people quit smoking tobacco.
The Business Trip
The Weekend Australian Magazine, November 13, 2022
A luxe psychedelic retreat for high-flying corporate types? Will Pavia is all in.
Colorado Voted to Decriminalize Psilocybin and Other Psychedelics
Time, November 11, 2022
Colorado voters have approved the broadest psychedelic legalization in the U.S., which would decriminalize five psychedelic substances and enable adults to receive psychedelics at licensed centers. The Associated Press called the vote for the measure, Proposition 122, on Friday morning; 92% of the votes were in as of 11 a.m., with 52.3% of voters in favor.
Researchers experiment with psychedelics to treat post-traumatic stress disorder
7.30, ABC, November 9, 2022
There are some effective therapies for people suffering from post-traumatic stress disorder, but they don’t work for everyone and with as many as one million Australians living with PTSD, the search for new treatments is gathering steam.
It’s driving a re-examination of treatments involving psychedelic drugs as James Elton reports.
With Promise of Legalization, Psychedelic Companies Joust Over Future Profits
The New York Times, October 25, 2022
Start-ups are filing scores of patent claims on psychedelics such as psilocybin.
Read the full PDF here.
The world’s first Phase 3 psilocybin clinical trial is about to commence
New Atlas, October 25, 2022
The world’s first Phase 3 human trial for day psilocybin therapy with psychological support due to commence by the end of 2022. The trial will enroll close to 1,000 participants and Compass is looking to FDA approval by the end of 2025.
Shroom A Magic Cure
Herald Sun, October 24, 2022
Melbourne team makes anorexia breakthrough.
Professor Arthur Christopoulos speaks at Academy of Law and Academy of Science Joint Symposium
Academy of Law and Academy of Science Joint Symposium, October 18, 2022
Yesterday, Professor Arthur Christopoulos, Dean of the Faculty of Pharmacy & Pharmaceutical Sciences, and inaugural Director of the Neuromedicines Discovery Centre at Monash University, spoke at the Academy of Law and Academy of Science Joint Symposium.
He spoke of the vast divide between science and the law, in reference to the scheduling of medicines, and particularly focusing on psilocybin and MDMA. As the TGA finalises the interim decision on the rescheduling of these medicines, it would be important to keep his words in mind.
Psychedelic Medicine Is Going Beyond PTSD and Depression
Lucid News, October 13, 2022
Though psychedelic treatments for a few major indications get all the headlines, there are many more conditions that psychedelic treatments are being investigated for.